Facchetti Giorgio, Petrella Francesco, Spaggiari Lorenzo, Rimoldi Isabella
Department of Pharmaceutical Sciences, University of Milan, Via Golgi 19, 20133 Milan, Italy.
Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
Eur J Med Chem. 2017 Dec 15;142:266-270. doi: 10.1016/j.ejmech.2017.07.063. Epub 2017 Aug 2.
Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in association with a third-generation antifolate is the front-line standard of care whereas any second-line treatment was approved for MPM thus making it a pathology that evokes the need for new therapeutic agents. Different platinum-drugs were synthesised and tested as an option for patients who are not candidates to cisplatin-based therapy. Among these, monofunctional cationic antineoplastic platinum compounds received a special attention in the last decade. Alternative strategies to the commonly used combination-therapy resulted from the use of Mesenchymal Stromal Cells (MSC) widely used in the field of regenerative medicine and recently proposed as natural carriers for a selective delivery of chemotherapeutic agents and from the use of immune checkpoint and kinase inhibitors. The present short review shed light on the recent state of art and the future perspectives relative to MPM therapy.
恶性胸膜间皮瘤（MPM）是一种侵袭性恶性肿瘤，对化疗具有高度抗性，患者的缓解率为20%，因此有效的治疗仍然是一项挑战。铂类化疗联合第三代抗叶酸剂是一线标准治疗方案，而任何二线治疗方案均未被批准用于MPM，因此这是一种需要新治疗药物的疾病。合成并测试了不同的铂类药物，作为不适合基于顺铂治疗的患者的一种选择。其中，单功能阳离子抗肿瘤铂化合物在过去十年中受到了特别关注。常用联合治疗的替代策略源于间充质基质细胞（MSC）的应用，MSC在再生医学领域广泛使用，最近被提议作为化疗药物选择性递送的天然载体，也源于免疫检查点和激酶抑制剂的应用。本简短综述阐明了MPM治疗的最新进展和未来前景。
